Current Status and Future Directions of Gene and Cell Therapy for Cystic Fibrosis

被引:0
|
作者
Uta Griesenbach
Eric W. F. W. Alton
机构
[1] Imperial College London,Department of Gene Therapy
[2] The UK Cystic Fibrosis Gene Therapy Consortium,Department of Gene Therapy
[3] Faculty of Medicine at the National Heart and Lung Institute,undefined
[4] Imperial College London,undefined
来源
BioDrugs | 2011年 / 25卷
关键词
Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cystic Fibrosis Patient; Airway Epithelial Cell; Airway Epithelium;
D O I
暂无
中图分类号
学科分类号
摘要
Although the development of gene therapy for cystic fibrosis (CF) was high priority for many groups in academia and industry in the first 10–15 years after cloning the cystic fibrosis transmembrane conductance regulator (CFTR) gene, more recently active research into CF gene therapy is only being performed by a small number of committed groups. However, despite the waning enthusiasm, which is largely due to the realization that gene transfer into lungs is more difficult than originally thought, and the fact that meaningful clinical trials are expensive and difficult to perform, gene therapy continues to hold promise for the treatment of CF lung disease. Problems related to repeat administration of adenovirus and adeno-associated virus-based vectors led to a focus on non-viral vectors in clinical trials. However, the recent evidence that lentiviral vectors may be able to evade the immune system and, thereby, allow for repeat administration and long-lasting expression opens new doors for the use of viral vectors in the context of CF gene therapy. In addition, early pre-clinical studies have recently been initiated to address cell therapy-based approaches for CF. In this review, we discuss recent developments with viral and non-viral vectors and cell therapy, and provide an update on clinical gene therapy studies.
引用
收藏
页码:77 / 88
页数:11
相关论文
共 50 条
  • [21] CURRENT STATUS AND FUTURE-PROSPECTS FOR THE TREATMENT OF LUNG-DISEASE IN CYSTIC-FIBROSIS BY GENE-THERAPY
    PORTEOUS, DJ
    PULMONARY PHARMACOLOGY, 1994, 7 (03): : 153 - 157
  • [22] Cell processing: Current status and future directions
    Stroncek, D
    Read, EJ
    YONSEI MEDICAL JOURNAL, 2004, 45 : 1 - 4
  • [23] Cystic fibrosis bone disease treatment: Current knowledge and future directions
    Putman, Melissa S.
    Anabtawi, Abeer
    Le, Trang
    Tangpricha, Vin
    Sermet-Gaudelus, Isabelle
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 : S56 - S65
  • [24] Cystic Fibrosis: Progress and Future Directions
    Cataletto, Mary
    PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY, 2015, 28 (04) : 195 - 195
  • [25] Microneedle-based technology for cell therapy: current status and future directions
    Chen, Bo Zhi
    Zhao, Ze Qiang
    Shahbazi, Mohammad-Ali
    Guo, Xin Dong
    NANOSCALE HORIZONS, 2022, 7 (07) : 715 - 728
  • [26] Systemic therapy in squamous cell carcinoma of the vulva: Current status and future directions
    Reade, Clare J.
    Eiriksson, Lua R.
    Mackay, Helen
    GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 780 - 789
  • [27] Status of gene therapy for cystic fibrosis lung disease
    Boucher, RC
    JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (04): : 441 - 445
  • [28] Gene therapy for cystic fibrosis:: present status and perspectives
    Pavirani, A
    Régulier, É
    Bellon, G
    Mehtali, M
    M S-MEDECINE SCIENCES, 1999, 15 (05): : 595 - 605
  • [29] Vaccine therapy for melanoma: Current status and future directions
    Terando, Alicia M.
    Faries, Mark B.
    Morton, Donald L.
    VACCINE, 2007, 25 : B4 - B16
  • [30] Current status and future directions of pharmacological therapy for acromegaly
    Mercado, Moises
    Espinosa, Etual
    Ramirez, Claudia
    MINERVA ENDOCRINOLOGICA, 2016, 41 (03) : 351 - 365